OTC Continuous Glucose Monitoring Program
Primary care, endocrinology and employer/wellness programs adding glucose monitoring for patients not on insulin.
$1,500 program advisory · device and consumables quoted directly by the manufacturerRequest a proposal
The device
Dexcom — Stelo over-the-counter CGM. Intended use per the manufacturer’s current FDA clearance or approval: over-the-counter continuous glucose monitoring. Indications, contraindications and training requirements are set by Dexcom; ClearLine confirms the current labeling with the manufacturer during the assessment.
What the advisory includes
Clinical and financial case for a Stelo over-the-counter CGM program at your site
Manufacturer engagement, quote and contract review with Dexcom or its authorized distributor
Credentialing, training, workflow and reimbursement plan
Go-live checklist and 90-day utilization review
How it works
1
Intake call: volumes, payer mix, current pathway
2
Program assessment and business case
3
Procurement support through contract
4
Launch plan and 90-day review
Who it’s for
Primary care, endocrinology and employer/wellness programs adding glucose monitoring for patients not on insulin.
OTC Continuous Glucose Monitoring Program — $1,500
Request a proposalClearLine Healthcare Consulting is an independent advisor and is not affiliated with or endorsed by Dexcom. Equipment is purchased from the manufacturer or its authorized distributor under their terms.